Psychology & Intimacy A New Frontier in Neuropharmacology: ETH Zurich Researchers Develop Compound 10 to Disrupt the Cellular Mechanisms of Alzheimer’s Disease October 1, 2026 Rebecca Shoemaker The global scientific community has long grappled with the profound complexities of neurodegenerative disorders, among which Alzheimer’s disease stands as one of the most formidable challenges in modern medicine. Despite…
Psychology & Intimacy New ETH Zurich Alzheimer’s Treatment Target and Compound 10 Show Promise in Preclinical Studies September 21, 2026 Rebecca Shoemaker The global scientific community continues to grapple with one of modern medicine’s most elusive challenges: halting the relentless progression of Alzheimer’s disease. Amid decades of incremental progress and numerous clinical…
Psychology & Intimacy ETH Zurich Researchers Develop Experimental Compound That Targets GRK2 Enzyme to Slow Alzheimer’s Progression and Protect Mitochondria September 14, 2026 Rebecca Shoemaker A team of molecular pharmacologists at ETH Zurich has developed an experimental chemical substance, designated as Compound 10, that offers a novel therapeutic approach to slowing the neurodegenerative progression of…
